Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amgen
Amgen to Participate in Dermatologic and Ophthalmic Drugs Advisory Committee Meeting in June
May 18th, 2008
Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has asked the Company to participate in a meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) on June 18, 2008. The DODAC will review data supporting the supplemental Biologic License Application (sBLA) submitted by Amgen for the use of ENBREL in treating pediatric patients with chronic moderate to severe plaque psoriasis, who are inadequately controlled with topical therapy or who have received systemic therapy or phototherapy. "Plaque psoriasis is a chronic disease of the immune system that can impair many aspects of the daily lives of children and teens. If approved...
Source: Medical Letter on the CDC & FDA (2008-05-18)
|
